Quick Answer
HALOZYME THERAPEUTICS, INC. reported Net Income of $316.89 million for fiscal year 2025.
HALOZYME THERAPEUTICS, INC. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | $316.89M | -28.6% |
| 2024 | $444.09M | +57.7% |
| 2023 | $281.59M | +39.3% |
| 2022 | $202.13M | -49.8% |
| 2021 | $402.71M | +212.0% |
| 2020 | $129.09M | +278.7% |
| 2019 | -$72.24M | +10.1% |
| 2018 | -$80.33M | -227.6% |
| 2017 | $62.97M | +161.1% |
| 2016 | -$103.02M | -219.6% |
| 2015 | -$32.23M | +52.9% |
| 2014 | -$68.38M | +18.1% |
| 2013 | -$83.48M | -55.9% |
| 2012 | -$53.55M | -170.9% |
| 2011 | -$19.77M | +62.9% |
| 2010 | -$53.24M | +8.8% |
| 2009 | -$58.36M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $175.22M | +27.9% | +6.1% |
| June 30, 2025 | $165.16M | +77.1% | +39.9% |
| March 31, 2025 | $118.09M | +53.7% | -13.8% |
| September 30, 2024 | $137.01M | +67.4% | +46.9% |
| June 30, 2024 | $93.25M | +24.7% | +21.4% |
| March 31, 2024 | $76.82M | +93.9% | -6.1% |
| September 30, 2023 | $81.84M | +32.8% | +9.5% |
| June 30, 2023 | $74.75M | +229.5% | +88.7% |
- HALOZYME THERAPEUTICS, INC. showed a decrease of -28.6% in Net Income compared to the prior fiscal year.
- Over the 2009–2025 period, HALOZYME THERAPEUTICS, INC.’s net income has grown by 643.0% (from -$58.36 million to $316.89 million).
- The most recent figure is from HALOZYME THERAPEUTICS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 17, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: